drugset
drugset / Trial / NCT02780323

Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

NCT02780323 ↗

Phase 4 Completed 119 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This Phase IV clinical study is to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Rheumatoid Arthritis Patients

Timeline

Start
2015-11-02
Primary completion
2017-12-26
Completion
2017-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified — —

Indications

rheumatoid arthritis